Selective in vivo binding of [3H]naltriben to δ-opioid receptors in mouse brain

European Journal of Pharmacology

Volumn 350, Issue 2-3, 1998, Pages 335-344

  Lever, John R ^a   Scheffel, Ursula ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Opioid receptor; Benzylidenenaltrexone; Binding; Brain; CD1 mouse; CXBK mouse; In vivo; Naltriben

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; 7 BENZYLIDENENALTREXONE; DELTA OPIATE RECEPTOR; NALTRIBEN; NALTRINDOLE; RADIOLIGAND; RECEPTOR SUBTYPE;

ARTICLE; BRAIN; DOSE RESPONSE; DRUG POTENCY; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

ANIMALS; BINDING, COMPETITIVE; BRAIN; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED STRAINS; NALTREXONE; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID, DELTA;

EID: 0032486119     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00268-4     Document Type: Article

References (51)

1. Benyo Z., Wahl M. Opiate receptor-mediated mechanisms in the regulation of cerebral blood flow. Cerebrovasc. Brain Metab. Rev. 8:1996;326-357.
2. Bilsky E.J., Bernstein R.N., Hruby V.J., Rothman R.B., Lai J., Porreca F. Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated knock-down of opioid receptors in vivo. J. Pharmacol. Exp. Ther. 277:1996;491-501.
3. Búzás B., Izenwasser S., Portoghese P.S., Cox B.M. Evidence for delta opioid receptor subtypes regulating adenylyl cyclase activity in rat brain. Life Sci. 54:1994;PL101-PL106.
4. Cha X.Y., Xu H., Rice K.C., Porreca F., Lai J., Ananthan S., Rothman R.B. Opioid peptide receptor studies: 1. Identification of a novel δ-opioid receptor binding site in rat brain membranes. Peptides. 16:1995;191-198.
5. 3H] DPDPE binding to striatal slices of mice Life Sci. 53:1993;1761-1765.
6. Delay-Goyet P., Ruiz-Gayo M., Baamonde A., Gacel G., Morgat J.-L., Roques B.P. Brain passage of BUBU, a highly selective and potent agonist for δ opioid receptors: in vivo binding and μ versus δ receptors occupancy. Pharmacol. Biochem. Behav. 38:1991;155-162.
7. 2]deltorphin-I: a high affinity, delta-selective opioid receptor ligand Peptides. 12:1991;825-830.
8. 3H] naltrindole binding to delta opioid receptors in mouse brain and mouse vas deferens: evidence for delta opioid receptor heterogeneity J. Pharmacol. Exp. Ther. 268:1994;836-846.
9. 2]deltorphin-I Synapse. 13:1993;231-240.
10. 14C] iodoantipyrine in the mouse J. Cereb. Blood Flow Metab. 8:1988;121-129.
11. 6]enkephalin and naltrindole 5́-isothiocyanate: evidence for delta receptor subtypes. J. Pharmacol. Exp. Ther. 257:1991;1069-1075.
12. 2-opioid receptors. Life Sci. 55:1994;PL121-PL126.
13. 1-opioid receptors in the antinociceptive effects of mexiletine in mice. Neurosci. Lett. 196:1995;169-172.
14. Knapp R.J., Malatynska E., Fang L., Li X., Babin E., Nguyen M., Santoro G., Varga E.V., Hruby V.J., Roeske W.R., Yamamura H.I. Identification of a human delta opioid receptor: cloning and expression. Life Sci. 54:1994;PL463-PL469.
15. Kong H., Raynor K., Yasuda K., Moe S.T., Portoghese P.S., Bell G.I., Reisine T. A single residue, aspartic acid 95, in the δ opioid receptor specifies selective high affinity agonist binding. J. Biol. Chem. 268:1993;23055-23058.
16. 3H] U-69593 a highly selective ligand for the opioid κ receptor Eur. J. Pharmacol. 109:1985;281-284.
17. Leighton G.E., Rodriguez R.E., Hill R.G., Hughes J. κ-Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat. Br. J. Pharmacol. 93:1988;553-560.
18. Leo A.J. Calculating log Poct from structures. Chem. Rev. 93:1993;1281-1306.
19. 3H] naltriben Soc. Neurosci. Abstr. 23:1997;397. (159.397).
20. 11C] methyl)naltrindole to δ-opioid receptors in mouse brain Eur. J. Pharmacol. 216:1992;459-460.
21. 1 subtype Life Sci. 58:1996;PL331-PL336.
22. 11C] methyl)naltrindole and PET Synapse. 24:1996;19-28.
23. Madar I., Lesser R.P., Krauss G., Zubieta J.K., Lever J.R., Kinter C.M., Ravert H.T., Musachio J.L., Mathews W.B., Dannals R.F., Frost J.J. Imaging of δ- and μ-opioid receptors in temporal lobe epilepsy by positron emission tomography. Ann. Neurol. 41:1997;358-367.
24. Mansour A., Khachaturian H., Lewis M.E., Akil H., Watson S.J. Anatomy of CNS opioid receptors. Trends Neurosci. 11:1988;308-314.
25. 2]deltorphin II in mice: evidence for delta receptor subtypes. J. Pharmacol. Exp. Ther. 258:1991;583-587.
26. 2, and delta opioid binding in the central nervous system of C57BL/6BY and CXBK (opioid receptor-deficient) mice. Brain Res. 360:1985;108-116.
27. Noble F., Cox B.M. Differential regulation of D1 dopamine receptor- and of A2a adenosine receptor-stimulated adenylyl cyclase by μ-, δ1-, and δ2-opioid agonists in rat caudate putamen. J. Neurochem. 65:1995;125-133.
28. Olianas M.C., Onali P. Participation of delta opioid receptor subtypes in the stimulation of adenylyl cyclase activity in rat olfactory bulb. J. Pharmacol. Exp. Ther. 275:1995;1560-1567.
29. Portoghese P.S., Sultana M., Nagase H., Takemori A.E. Application of the message-address concept in the design of highly potent and selective non-peptide δ opioid receptor antagonists. J. Med. Chem. 31:1988;281-282.
30. Portoghese P.S., Sultana M., Takemori A.E. Naltrindole, a highly selective and potent non-peptide δ opioid receptor antagonist. Eur. J. Pharmacol. 146:1988;185-186.
31. Portoghese P.S., Nagase H., MaloneyHuss K.E., Lin C.-E., Takemori A.E. Role of spacer and address components in peptidomimetic δ opioid receptor antagonists related to naltrindole. J. Med. Chem. 34:1991;1715-1720.
32. Portoghese P.S., Sultana M., Nagase H., Takemori A.E. A highly selective δ1-opioid receptor antagonist: 7-benzylidenenaltrexone. Eur. J. Pharmacol. 218:1992;195-196.
33. Rady J.J., Takemori A.E., Portoghese P.S., Fujimoto J.M. Supraspinal delta receptor subtype activity of heroin and 6-monoacetylmorphine in Swiss Webster mice. Life Sci. 55:1994;603-609.
34. 5]enkephalin, in the μ-opioid receptor deficient CXBK mouse. Eur. J. Pharmacol. 216:1992;453-456.
35. Raynor K., Kong H., Chen Y., Yasuda K., Yu L., Bell G.I., Reisine T. Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptors. Mol. Pharmacol. 45:1994;330-334.
36. Reisine T. Opiate receptors. Neuropharmacology. 34:1995;463-472.
37. Reith M.E.A., Sershen H., Vadasz C., Lajtha A. Strain differences in opiate receptors in mouse brain. Eur. J. Pharmacol. 74:1981;377-380.
38. Robson L.E., Gillan M.G.C., Kosterlitz H.W. Species differences in the concentrations and distributions of opioid binding sites. Eur. J. Pharmacol. 112:1985;65-71.
39. 11C] Naltriben: synthesis and biodistribution of a selective δ2-opioid receptor antagonist for PET. 11th International Symposium on Radiopharmaceutical Chemistry Abstracts. Vancouver, BC, Canada, 13-17 August, pp. 401-403.
40. Schmidhammer H., Burkard W.P., Eggstein-Aeppli L., Smith C.F.C. Synthesis and biological evaluation of 14-alkoxymorphinans: 2. (-)-N-(cyclopropylmethyl)-4,14-dimethoxymorphinan-6-one, a selective μ opioid receptor antagonist. J. Med. Chem. 32:1989;418-421.
41. Simonin F., Befort K., Gavériaux-Ruff C., Matthes H., Nappey V., Lannes B., Micheletti G., Kieffer B. The human δ-opioid receptor: genomic organization, cDNA cloning, functional expression, and distribution in human brain. Mol. Pharmacol. 46:1994;1015-1021.
42. Sofuoglu M., Portoghese P.S., Takemori A.E. Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. J. Pharmacol. Exp. Ther. 257:1991;676-680.
43. Sofuoglu M., Portoghese P.S., Takemori A.E. δ-Opioid receptor binding in mouse brain: evidence for heterogeneous binding sites. Eur. J. Pharmacol. 216:1992;273-277.
44. Suzuki T., Mori T., Tsuji M., Misawa M., Nagase H. The role of δ-opioid receptor subtypes in cocaine- and methamphetamine-induced place preferences. Life Sci. 55:1994;PL339-PL344.
45. 2 opioid receptor agonists in mice. Psychopharmacology. 124:1996;211-218.
46. Takemori A.E., Portoghese P.S. Enkephalin antinociception in mice is mediated by δ1- and δ2-opioid receptors in the brain and spinal cord, respectively. Eur. J. Pharmacol. 242:1993;145-150.
47. Traynor J.R., Elliott J. δ-Opioid receptor subtypes and cross-talk with μ-receptors. Trends Pharmacol. Sci. 14:1993;84-86.
48. Tseng L.F., Narita M., Mizoguchi H., Kawai K., Mizusuna A., Kamei J., Suzuki T., Nagase H. Delta-1 opioid receptor-mediated antinociceptive properties of a nonpeptidic delta opioid receptor agonist, (-)Tan-67, in the mouse spinal cord. J. Pharmacol. Exp. Ther. 280:1997;600-605.
49. Upton R.N., Ludbrook G.L., Gray E.C., Grant C. The cerebral pharmacokinetics of meperidine and alfentanil in conscious sheep. Anesthesiology. 86:1997;1317-1325.
50. Xu H., Partilla J.S., de Costa B.R., Rice K.C., Rothman R.B. Differential binding of opioid peptides and other drugs to two subtypes of opioid δncx binding sites in mouse brain: further evidence for δ receptor heterogeneity. Peptides. 14:1993;893-907.
51. Zaki P.A., Bilsky E.J., Vanderah T.W., Lai J., Evans C.J., Porreca F. Opioid receptor types and subtypes: the δ receptor as a model. Annu. Rev. Pharmacol. Toxicol. 36:1996;379-401.